Asian equity benchmarks are trading higher in early deals on Thursday, as the possible progress on an experimental treatment for COVID-19, lifted investor sentiments. Gilead Sciences cited positive data emerging from the National Institute of Allergy and Infectious Diseases' study of its investigational antiviral remdesivir for the treatment of pandemics. Besides, optimism around the easing of coronavirus-led lockdowns also buoyed investments. Japan's Nikkei which resumed trading after a holiday on Wednesday, is sharply higher and in line with positive trend in Wall Street stocks overnight. Stock markets of Hong Kong and South Korea are closed for a holiday. Among the Asian markets, Singapore, Indonesia, Taiwan, Shanghai and Malaysia are trading in green.
Nikkei 225 up by 556.94 points, 2.82% to 20,328.13, Straits Times rose by 52.96 points or 2.06% to 2,627.69, Taiwan Weighted enlarged 228.71 points or 2.12% to 11,000.93, Jakarta Composite climbed by 118.16 points or 2.59% to 4,685.48, Shanghai higher by 39.14 points or 1.39% to 2,861.58 and FTSE Bursa Malaysia KLCI increased by 19.90 points or 1.44% to 1,400.20.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: